$2.5
Century Therapeutics is a biotechnology business based in the US. Century Therapeutics shares (IPSC) are listed on the NASDAQ and all prices are listed in US Dollars. Century Therapeutics employs 152 staff and has a trailing 12-month revenue of around $1.4 million.
Our top picks for where to buy Century Therapeutics stock
How to buy Century Therapeutics stock
- Choose a stock trading platform. Use our comparison table
- Open an account. Provide your personal information and sign up.
- Fund your account. Deposit funds into your account by linking your banking information or transfer funds from another trading account.
- Search for the stock name – IPSC. Search for the stock by name or ticker symbol.
- Buy the stock. Place your order. It's that simple.
Buy Century Therapeutics stock from these online trading platforms
Compare special offers, low fees and a wide range of investment options among top trading platforms.Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
Century Therapeutics stock price (NASDAQ: IPSC)
Use our graph to track the performance of IPSC stocks over time.Century Therapeutics shares at a glance
Latest market close | $2.38 |
---|---|
52-week range | $1.28 - $5.51 |
50-day moving average | $2.87 |
200-day moving average | $3.10 |
Wall St. target price | $12.80 |
PE ratio | N/A |
Dividend yield | N/A (0%) |
Earnings per share (TTM) | $-2.22 |
Is it a good time to buy Century Therapeutics stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Century Therapeutics price performance over time
Historical closes compared with the close of $2.38 from 2024-07-25
1 week (2024-07-19) | -4.80% |
---|---|
1 month (2024-06-27) | -5.93% |
3 months (2024-04-26) | -17.36% |
6 months (2024-01-26) | -43.60% |
1 year (2023-07-27) | -20.67% |
---|---|
2 years (2022-07-27) | -77.76% |
3 years (2021-07-27) | 27.81 |
5 years (2019-07-23) | N/A |
Century Therapeutics financials
Revenue TTM | $1.4 million |
---|---|
Gross profit TTM | $5.2 million |
Return on assets TTM | -19.33% |
Return on equity TTM | -58.66% |
Profit margin | 0% |
Book value | $2.75 |
Market Capitalization | $211.3 million |
TTM: trailing 12 months
Century Therapeutics share dividends
We're not expecting Century Therapeutics to pay a dividend over the next 12 months.
You may also wish to consider:
- Pfizer (PFE.US) (5.57% forward annual dividend yield)
Century Therapeutics share price volatility
Over the last 12 months, Century Therapeutics's shares have ranged in value from as little as $1.28 up to $5.51. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Century Therapeutics's is 1.404. This would suggest that Century Therapeutics's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
To put Century Therapeutics's beta into context you can compare it against those of similar companies.
- Prelude Therapeutics Inc (PRLD.US): 1.54
- Greenwich Lifesciences Inc (GLSI.US): 3.333
- Pfizer (PFE.US): 0.634
Century Therapeutics overview
Century Therapeutics, Inc. , a biotechnology company, engages in the development of genetically engineered allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed, refractory B-cell lymphoma. The company is also involved in the development of CNTY-102, a bi-specific CD19 + CD22 CAR-iT product candidate for relapsed, refractory B-cell lymphoma and other B-cell malignancies; and CNTY-107, a Nectin-4 CAR-iT targeted product candidate for Nectin-4 positive solid tumors. In addition, it has a strategic collaboration with Bristol-Myers Squibb Company to develop and commercialize up to four iNK or iT programs, including CNTY-104, a multi-specific collaboration program targeting acute myeloid leukemia; and CNTY-106, a multi-specific collaboration program for multiple myeloma. The company was incorporated in 2018 and is headquartered in Philadelphia, Pennsylvania. .
Frequently asked questions
nullWhat percentage of Century Therapeutics is owned by insiders or institutions?
Currently 28.217% of Century Therapeutics shares are held by insiders and 53.674% by institutions. How many people work for Century Therapeutics?
Latest data suggests 152 work at Century Therapeutics. When does the fiscal year end for Century Therapeutics?
Century Therapeutics's fiscal year ends in December. Where is Century Therapeutics based?
Century Therapeutics's address is: 25 North 38th Street, Philadelphia, PA, United States, 19104 What is Century Therapeutics's ISIN number?
Century Therapeutics's international securities identification number is: US15673T1007
More guides on Finder
-
Opto review 2024: $0 commission, fractional theme investing
Trade commission-free stocks and ETFs with Opto, and stay ahead by spotting emerging trends through thematic investing.
-
Best paper trading platforms to practice trading with fake money [2024]
Check out our picks of the best paper trading platforms to practice trading and investing with fake money.
-
Put options explained
Learn the basics of put options: what they are, how they work and a few examples.
-
Best broker cash sweep rates for July 2024
Check out our picks for the brokers with the best cash sweep rates on uninvested cash.
-
7 best day trading platforms of July 2024
These are the best day trading platforms, according to Finder’s comprehensive analysis.
-
Today’s best brokerage account bonuses [Signup and transfer promos]
Explore the best bonuses for opening a new brokerage account.
-
11 apps like Webull you need to consider
Looking for a discount broker like Webull that offers something different? Here are some of the top alternatives to consider.
-
How to invest in the S&P 500 in 2024
What you need to know about investing in the leading indicator for the overall US stock market.
-
7 best ways to invest $10K
Check out our 7 ideas for how to invest $10K to maximize your money.
-
5 best ETFs for 2024
Check out the best-performing ETFs so far in 2024.
Ask a question